Ergosta-2,24-dien-26-oic acid, 5,6-epoxy-22-hydroxy-4,27-dimethoxy-1-oxo-, δ-lactone, (4β,5β,6β,22R)-

Request For Quotation
Ergosta-2,24-dien-26-oic acid, 5,6-epoxy-22-hydroxy-4,27-dimethoxy-1-oxo-, δ-lactone, (4β,5β,6β,22R)- Basic information
Product Name:Ergosta-2,24-dien-26-oic acid, 5,6-epoxy-22-hydroxy-4,27-dimethoxy-1-oxo-, δ-lactone, (4β,5β,6β,22R)-
Synonyms:Ergosta-2,24-dien-26-oic acid, 5,6-epoxy-22-hydroxy-4,27-dimethoxy-1-oxo-, δ-lactone, (4β,5β,6β,22R)-;4,27-Dimethyl withaferin A
CAS:1777780-95-6
MF:C30H42O6
MW:498.65
EINECS:
Product Categories:
Mol File:1777780-95-6.mol
Ergosta-2,24-dien-26-oic acid, 5,6-epoxy-22-hydroxy-4,27-dimethoxy-1-oxo-, δ-lactone, (4β,5β,6β,22R)- Structure
Ergosta-2,24-dien-26-oic acid, 5,6-epoxy-22-hydroxy-4,27-dimethoxy-1-oxo-, δ-lactone, (4β,5β,6β,22R)- Chemical Properties
Boiling point 628.5±55.0 °C(Predicted)
density 1.19±0.1 g/cm3(Predicted)
Safety Information
MSDS Information
Ergosta-2,24-dien-26-oic acid, 5,6-epoxy-22-hydroxy-4,27-dimethoxy-1-oxo-, δ-lactone, (4β,5β,6β,22R)- Usage And Synthesis
Uses4,27-Dimethyl withaferin A is a synthetic analog of withanolide natural products. 4,27-Dimethyl withaferin A has the potential for the research of neurodegenerative diseases (extracted from patent WO2015077780A1)[1].
References[1] Anthony A. SHAW, et al. Withanolides useful for the treatment of neurodegenerative diseases. Patent WO2015077780A1.
Ergosta-2,24-dien-26-oic acid, 5,6-epoxy-22-hydroxy-4,27-dimethoxy-1-oxo-, δ-lactone, (4β,5β,6β,22R)- Preparation Products And Raw materials
Tag:Ergosta-2,24-dien-26-oic acid, 5,6-epoxy-22-hydroxy-4,27-dimethoxy-1-oxo-, δ-lactone, (4β,5β,6β,22R)-(1777780-95-6) Related Product Information
Human IgG1, kappa Isotype Control beta-D-Fructopyranose Anti-Mouse Ly6G Antibody (1A8) RAT IGG2B, KAPPA 3X FLAG peptide TFA Phaseolus vulgaris agglutinin